Vaccine pipeline has grown during the past two decades with more early-stage trials from small and medium-size companies

Health Affairs

Volumn 35, Issue 2, 2016, Pages 219-226

  Hwang, Thomas J ^a   Kesselheim, Aaron S ^b  

^a Bain Capital   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ARTICLE; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HUMAN; PIPELINE; PUBLIC HEALTH PROBLEM; PUBLIC-PRIVATE PARTNERSHIP; UNITED STATES; VACCINATION; CLINICAL TRIAL (TOPIC); FACTUAL DATABASE; MEDICAL RESEARCH; STATISTICS AND NUMERICAL DATA; TRENDS;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; HUMANS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; VACCINES;

EID: 84958672783     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2015.1073     Document Type: Article

References (32)

1. Strategic Advisory Group of Experts on Immunization. 2014 assessment report of the Global Vaccine Action Plan [Internet]. Geneva: World Health Organization; 2014 [cited 2015 Dec 16]. Available from: http://www.who.int/immunization/policy/sage/en/
2. Stack ML, Ozawa S, Bishai DM, Mirelman A, Tam Y, Niessen L, et al. Estimated economic benefits during the "Decade of Vaccines" include treatment savings, gains in labor productivity. Health Aff (Millwood). 2011;30(6):1021-8.
3. Ozawa S, Stack ML, Bishai DM, Mirelman A, Friberg IK, Niessen L, et al. During the "Decade of Vaccines, " the lives of 6.4 million children valued at $231 billion could be saved. Health Aff (Millwood). 2011; 30(6):1010-20.
4. Harris JE.Why we don't have an HIV vaccine, and how we can develop one. Health Aff (Millwood). 2009; 28(6):1642-54.
5. Barker LF, Leadman AE, Clagett B. The challenges of developing new tuberculosis vaccines. Health Aff (Millwood). 2011;30(6):1073-9.
6. Darrow JJ, Kesselheim AS. A new wave of vaccines for non-communicable diseases: what are the regulatory challenges? Food Drug Law J. 2015;70(2):243-58.
7. Avorn J, Kesselheim AS. The 21st Century Cures Act-will it take us back in time? N Engl J Med. 2015; 372(26):2473-5.
8. Offit PA.Why are pharmaceutical companies gradually abandoning vaccines? Health Aff (Millwood). 2005;24(3):622-30.
9. Coleman MS, Sangrujee N, Zhou F, Chu S. Factors affecting U.S. manufacturers' decisions to produce vaccines. Health Aff (Millwood). 2005; 24(3):635-42.
10. Lieu TA, McGuire TG, Hinman AR. Overcoming economic barriers to the optimal use of vaccines. Health Aff (Millwood). 2005;24(3):666-79.
11. Stéphenne J. Vaccines as a global imperative-a business perspective. Health Aff (Millwood). 2011;30(6): 1042-8.
12. Hwang TJ, Carpenter D, Kesselheim AS. Target small firms for antibiotic innovation. Science. 2014; 344(6187):967-9.
13. Sanseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, Cardon LR, et al. Use of genome-wide association studies for drug repositioning. Nat Biotechnol. 2012;30(4):317-20.
14. Davis MM, Butchart AT, Wheeler JR, Coleman MS, Singer DC, Freed GL. Failure-to-success ratios, transition probabilities, and phase lengths for prophylactic vaccines versus other pharmaceuticals in the development pipeline. Vaccine. 2011;29(51):9414-6.
15. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood). 2006;25(2):420-8.
16. Daniel GW, Cazé A, Romine MH, Audibert C, Leff JS, McClellan MB. Improving pharmaceutical innovation by building a more comprehensive database on drug development and use. Health Aff (Millwood). 2015;34(2):319-27.
17. Food and Drug Administration. Biological approvals by year [Internet]. Silver Spring (MD): FDA; [last updated 2010 Feb 22; cited 2015 Dec 16]. Available from: http://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/BiologicalApprovalsbyYear/default.htm
18. Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet. 2008;371(9629): 2019-25.
19. Behrens RH, Cramer JP, Jelinek T, Shaw H, von Sonnenburg F, Wilbraham D, et al. Efficacy and safety of a patch vaccine containing heat-labile toxin fromEscherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala. Lancet Infect Dis. 2014;14(3): 197-204.
20. Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med. 2011; 364(6):535-41.
21. Davis MM, Butchart AT, Coleman MS, Singer DC, Wheeler JR, Pok A, et al. The expanding vaccine development pipeline, 1995-2008. Vaccine. 2010;28(5):1353-6.
22. Pronker ES, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD. Risk in vaccine research and development quantified. PLoS One. 2013;8(3):e57755.
23. Kohli MA, Farkouh RA, Maschio MJ, McGarry LJ, Strutton DR, Weinstein MC. Despite high cost, improved pneumococcal vaccine expected to return 10-year net savings of $12 billion. Health Aff (Millwood). 2015; 34(7):1234-40.
24. Kesselheim A. Safety, supply, and suits-litigation and the vaccine industry. N Engl J Med. 2011;364(16): 1485-7.
25. Falit BP, Singh SC, Brennan TA. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers. Health Aff (Millwood). 2015;34(2): 294-301.
26. Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ. 2008;86(2):140-6.
27. Nossal GJV. Vaccines and future global health needs. Philos Trans R Soc Lond B Biol Sci. 2011;366(1579): 2833-40.
28. Plowe CV. Vaccine-resistant malaria. N Engl J Med. 2015;373(21):2082-3.
29. Ulmer JB, Valley U, Rappuoli R. Vaccine manufacturing: challenges and solutions. Nat Biotechnol. 2006;24(11):1377-83.
30. White House. New executive actions to combat antibiotic resistance and protect public health. White House Blog [blog on the Internet]. 2014 Sep 18 [cited 2015 Dec 16]. Available from: https://www.whitehouse.gov/blog/2014/09/18/new-executiveactions-combat-antibioticresistance-and-protect-public-health
31. Plotkin SA, Mahmoud AA, Farrar J. Establishing a global vaccine-development fund. N Engl J Med. 2015; 373(4):297-300.
32. Hwang TJ, Keshavjee S. Global financing and long-term technical assistance for multidrug-resistant tuberculosis: scaling up access to treatment. PLoS Med. 2014;11(9): e1001738.